Page 109 - 2020_11-Haematologica-web

Early disease progression in EMZL
References
1. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17): 2082-2092.
2. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013; 119(3):629-638.
3. Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treat- ment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66(2): 153-171.
4. Isaacson PG, Chott A, Nakamura S, Muller- Hermelink HK, Harris NL, Swerdlow S. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon: IARC. 2008:214-217.
5. Thieblemont C. Clinical presentation and management of marginal zone lym- phomas. Hematology Am Soc Hematol Educ Program. 2005:307-313.
6. Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and pro- gression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905-1912.
7. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409-1417.
8. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after
rituximab plus cyclophosphamide, doxoru- bicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
9. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil pro- duces superior event-free survival in the treatment of patients with extranodal mar- ginal-zone B-cell lymphoma: 5-year analy- sis of the IELSG-19 randomized study. J Clin Oncol. 2013;31(5):565-572.
10. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analy- ses published in cancer journals. Br J Cancer. 1995;72(2):511-518.
11. Bland JM, Altman DG. The logrank test. BMJ. 2004;328(7447):1073.
12. International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lym- phoma. N Engl J Med. 1993;329(14):987- 994.
13. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
14. Lockmer S, Ostenstad B, Hagberg H, et al. Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol. 2018 Oct 4. [Epub ahead of print]
15. Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112-1120.
16. Lansigan F, Barak I, Pitcher B, et al. The prognostic significance of PFS24 in follicu- lar lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med. 2019;8(1):165- 173.
17. Maurer MJ, Bachy E, Ghesquieres H, et al.
18.
19.
20.
21.
22.
23.
24.
Early event status informs subsequent out- come in newly diagnosed follicular lym- phoma. Am J Hematol. 2016;91(11):1096- 1101.
Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6): 1202-1208.
Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on pre- dicting outcomes in non-follicular indolent B-cell lymphomas. Am J Hematol. 2019;94(6):658-666.
Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94(5):585-596.
Luminari S, Marcheselli L, Defrancesco I, et al. Early progression as a predictor of sur- vival in marginal zone lymphomas: an analysis from the prospective international NF10 study by Fondazione Italiana Linfomi. Blood. 2019;134(10):798-801. Alderuccio JP, Zhao W, Desai A, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018 Oct 12. [Epub ahead of print] Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al. Histologic transfor- mation in marginal zone lymphomas. Ann Oncol. 2015;26(11):2329-2335.
Meyer AH, Stroux A, Lerch K, et al. Transformation and additional malignan- cies are leading risk factors for an adverse course of disease in marginal zone lym- phoma. Ann Oncol. 2014;25(1):210-215.
haematologica | 2020; 105(11)
2597